Last reviewed · How we verify
Sofosbuvir/Velpatasvir/Voxilaprevir
This combination inhibits three key hepatitis C virus enzymes (NS5B polymerase, NS5A protein, and NS3/4A protease) to block viral replication.
This combination inhibits three key hepatitis C virus enzymes (NS5B polymerase, NS5A protein, and NS3/4A protease) to block viral replication. Used for Chronic hepatitis C virus infection (genotypes 1-6), including treatment-experienced patients with compensated cirrhosis.
At a glance
| Generic name | Sofosbuvir/Velpatasvir/Voxilaprevir |
|---|---|
| Also known as | Vosevi, SOF/VEL/VOX, GS-7977/GS-5816/GS-9857 |
| Sponsor | Peking University People's Hospital |
| Drug class | Direct-acting antiviral (DAA) combination; NS5B polymerase inhibitor + NS5A inhibitor + NS3/4A protease inhibitor |
| Target | HCV NS5B polymerase, HCV NS5A protein, HCV NS3/4A protease |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Sofosbuvir is a nucleotide analog that inhibits the NS5B RNA-dependent RNA polymerase. Velpatasvir inhibits the NS5A protein, which is essential for viral replication and assembly. Voxilaprevir inhibits the NS3/4A serine protease. Together, these three agents target different steps of the HCV lifecycle, providing a pangenotypic, direct-acting antiviral regimen with high barrier to resistance.
Approved indications
- Chronic hepatitis C virus infection (genotypes 1-6), including treatment-experienced patients with compensated cirrhosis
Common side effects
- Headache
- Fatigue
- Diarrhea
- Nausea
- Asthenia
Key clinical trials
- The Kentucky Viral Hepatitis Treatment Study (PHASE4)
- Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy (PHASE4)
- Impact of Direct-acting Antiviral Drugs on The Patterns of Gut Microbiota in Patients With HCV Related Chronic Liver Diseases
- Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy (PHASE4)
- The Efficacy of Vosevi in Treating DAA-experienced Patients
- A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
- A Study of Chronic Hepatitis C Patients Treated With SOF/VEL/VOX
- Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: